First-line treatment with ibrutinib plus venetoclax provided high rates of undetectable minimal residual disease in peripheral blood and bone marrow of patients with chronic lymphocytic leukemia.
Gina Mauro
Advertisement
Articles by Gina Mauro
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves T-DXd Plus Pertuzumab in Metastatic HER2+ Breast Cancer
2
FDA Grants National Priority Voucher to Teclistamab/Daratumumab in RRMM
3
Omitting Sentinel Lymph Node Biopsy Is Safe in Select Patients With HR+ Early Breast Cancer
4
How Might CTO1681 Prevent CRS After CAR T-Cell Therapy in DLBCL?
5
